Wegovy AKA: Every Name This Medicine Goes By, and Why It Matters

The decision you're probably trying to make: which of these names is the right one to look into?

People arrive at this question from different directions. Some have seen Ozempic mentioned on social media alongside weight loss and want to know whether it's the same as Wegovy. Others have been offered semaglutide by a private clinic and are unsure what that means. A question our prescribers hear most weeks is some version of: "Is Wegovy just another name for Ozempic?" The short answer is that they share an active ingredient but hold different licences for different conditions.

Semaglutide is a GLP-1 receptor agonist, it works by mimicking a gut hormone that signals fullness and slows the rate at which the stomach empties. Novo Nordisk brought it to market under three names for three distinct purposes: Wegovy (injection) for weight management, Ozempic for type 2 diabetes, and Rybelsus as an oral tablet for type 2 diabetes. The dose strengths differ across these products, and so does the regulatory permission for what conditions they can be prescribed to treat.

The NHS semaglutide medicines page sets this out plainly, and it's the clearest starting point if you want an official source. For someone seeking weight management treatment, the relevant product is Wegovy, and, as of summer 2026, that includes both the injection and the newly approved tablet.

Ozempic and Rybelsus: why these names keep appearing in weight-loss conversations

Ozempic is a subcutaneous injection used in type 2 diabetes management. It contains semaglutide at doses up to 2mg weekly. During its diabetes trials, patients lost weight as a secondary effect, and that observation spread quickly. The result is a persistent public association between the Ozempic name and weight loss, an association that is not reflected in its UK marketing authorisation.

The MHRA has been clear: Ozempic is not licensed for weight loss in the UK, and prescribing it for that purpose would be off-label. Separately, supplies of Ozempic became constrained when demand from people seeking it for weight management outpaced the supply intended for diabetes patients, a situation the MHRA flagged publicly. If you're looking for semaglutide for weight management, Wegovy is the product with the right UK licence for that purpose.

Rybelsus is oral semaglutide at 3mg, 7mg and 14mg, doses calibrated for blood sugar control in type 2 diabetes. These strengths are different from the Wegovy tablet schedule (1.5mg, 4mg, 9mg, up to 25mg), and the two products are not interchangeable. Rybelsus for weight loss would also be off-label in the UK. The distinction matters practically: a prescription for Rybelsus is not a prescription for Wegovy tablets, even though both are oral semaglutide.

What Wegovy actually refers to in 2026: injection, tablet, and the 7.2mg update

The Wegovy injection has been licensed in the UK for weight management for adults with a BMI of 30 or above, or 27 or above alongside a weight-related health condition. The standard injection titration runs from 0.25mg weekly up to 2.4mg, with the prescriber guiding the schedule, and you can read about how Wegovy 1mg fits into that early titration phase if you want to understand where treatment typically begins. In January 2026 the MHRA approved a higher 7.2mg maintenance dose, and a dedicated single-dose 7.2mg pen was authorised on 14 April 2026, details confirmed by the UK government's announcement at gov.uk. That pen is for adults with obesity (BMI 30 or above) only.

On 11 June 2026 the MHRA approved the Wegovy tablet for weight management, making the UK the first country in Europe to do so. The tablet starts at 1.5mg daily and escalates to a 25mg maintenance dose, a completely separate schedule from the Rybelsus diabetes tablet, and those who want detail on the intermediate steps can find out more about how Wegovy 2mg sits within the dose escalation journey. Exploring the full Wegovy overview or looking at weight-loss treatment options more broadly can help you see how these formulations fit together.

If you're weighing up the injection against the tablet, there are practical differences worth understanding: the tablet requires a strict morning routine (empty stomach, plain water, 30-minute wait before food or other medicines), while the injection is once weekly and needs refrigeration. Neither choice is straightforwardly better, it depends on your routine and what your prescriber considers appropriate for you.

Cost, access, and next steps

On the NHS, Wegovy is available through specialist weight management services under NICE guidance, with strict eligibility criteria and commonly long waiting times. Private treatment is the route most people take when they don't meet NHS criteria or prefer not to wait. If you're thinking about what that involves financially, the Wegovy cost guide covers what private treatment typically includes and what to watch for in pricing. It's also worth knowing that a legitimate private prescription for any of these medicines requires a genuine clinical assessment, not just a quick online form with no clinical oversight.

At nume, every consultation is personally reviewed by a GPhC-registered Independent Prescriber, the same day. The service covers Wegovy and the titration process from the starting dose through to maintenance, with clinical re-review before every repeat. If you'd like to explore whether semaglutide for weight management is appropriate for you, the place to start is a free consultation with our clinical team.